|
Aigner A.
Nonviral in vivo delivery of therapeutic small
interfering RNAs.
Curr Opin Mol Ther 9(4)
(2007) 345-352
Aigner A.
Tumor-targeting nanosystems for the delivery of siRNA.
Nanomedicine 2(4)
(2007) 569-572
Aigner A.
RNAi through short interfering RNA (siRNAs) as a novel
therapeutic strategy
Adv Gene Mol Cell Ther 1
(2007) 44-55
Aigner A.
Applications of RNA interfence: current state and
prospects for siRNA-based strategies in vivo
Appl Microbiol Biotechnol 76(1) (2007) 9-21
Knüpfer H, Preiss R:
Significance of interleukin-6 (IL-6) in breast cancer (review).
Breast Cancer Res Treat 102(2) (2007) 129-135
Teichert J, Baumann F, Chao Q, Franklin C,
Bailey B,
Henning L, Caca K, Schoppmeyer K, Patzak U, Preiss R:
Characterization of two phase I metabolites of bendamustine in human
liver microsomes and in cancer patients treated with bendamustine
hydrochloride.
Cancer Chemother Pharmacol 59(6) 2007 759-770
Keller A, Wu Z, Kratzsch J, Keller E, Blum
WF, Kniess A,
Preiss R, Teichert J, Strasburger CJ, Bidlingmaier M:
Pharmacokinetics and pharmacodynamics of GH: dependence on route and
dosage of administration.
Eur J Endocrinol 156(6) 2007 647-653
Schoppmeyer K, Kreth F, Wiedmann M, Mossner
J, Preiss R,
Caca K:
A pilot study of bendamustine in advanced bile duct cancer.
Anticancer Drugs 18 (6) 2007 697-702
Tassi E,
Walter S, Aigner A, Cabal-Manzano R H, Ray R, Reier P J, Wellstein A.
Effects on neurite outgrowth and cell survival of a secreted fibroblast
growth factor binding protein upregulated during spinal cord injury
Am J Physiol 293(2)
(2007) R775-783
|